Rebekah Wigton1, Jocham Radua2, Paul Allen1, Bruno Averbeck3, Andreas Meyer-Lindenberg4, Philip McGuire5, Sukhi S Shergill5, Paolo Fusar-Poli5. 1. The Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK. 2. The Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK and Fidmag, Cibersam, Sant Boi de Llobregat, Barcelona, Spain. 3. Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. 4. Central Institute of Mental Health, Medical Faculty Mannheim-Heidelberg University, Mannheim, Germany. 5. Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK.
Abstract
BACKGROUND: Oxytocin (OXT) plays a prominent role in social cognition and may have clinical applications for disorders such as autism, schizophrenia and social anxiety. The neural basis of its mechanism of action remains unclear. METHODS: We conducted a systematic literature review of placebo-controlled imaging studies using OXT as a pharmacological manipulator of brain activity. RESULTS: We identified a total of 21 studies for inclusion in our review, and after applying additional selection criteria, 11 of them were included in our fMRI voxel-based meta-analysis. The results demonstrate consistent alterations in activation of brain regions, including the temporal lobes and insula, during the processing of social stimuli, with some variation dependent on sex and task. The meta-analysis revealed significant left insular hyperactivation after OXT administration, suggesting a potential modulation of neural circuits underlying emotional processing. LIMITATIONS: This quantitative review included only a limited number of studies, thus the conclusions of our analysis should be interpreted cautiously. This limited sample size precluded a more detailed exploration of potential confounding factors, such as sex or other demographic factors, that may have affected our meta-analysis. CONCLUSION: Oxytocin has a wide range of effects over neural activity in response to social and emotional processing, which is further modulated by sex and task specificity. The magnitude of this neural activation is largest in the temporal lobes, and a meta-analysis across all tasks and both sexes showed that the left insula demonstrated the most robust activation to OXT administration.
BACKGROUND:Oxytocin (OXT) plays a prominent role in social cognition and may have clinical applications for disorders such as autism, schizophrenia and social anxiety. The neural basis of its mechanism of action remains unclear. METHODS: We conducted a systematic literature review of placebo-controlled imaging studies using OXT as a pharmacological manipulator of brain activity. RESULTS: We identified a total of 21 studies for inclusion in our review, and after applying additional selection criteria, 11 of them were included in our fMRI voxel-based meta-analysis. The results demonstrate consistent alterations in activation of brain regions, including the temporal lobes and insula, during the processing of social stimuli, with some variation dependent on sex and task. The meta-analysis revealed significant left insular hyperactivation after OXT administration, suggesting a potential modulation of neural circuits underlying emotional processing. LIMITATIONS: This quantitative review included only a limited number of studies, thus the conclusions of our analysis should be interpreted cautiously. This limited sample size precluded a more detailed exploration of potential confounding factors, such as sex or other demographic factors, that may have affected our meta-analysis. CONCLUSION:Oxytocin has a wide range of effects over neural activity in response to social and emotional processing, which is further modulated by sex and task specificity. The magnitude of this neural activation is largest in the temporal lobes, and a meta-analysis across all tasks and both sexes showed that the left insula demonstrated the most robust activation to OXT administration.
Authors: Brooks King-Casas; Damon Tomlin; Cedric Anen; Colin F Camerer; Steven R Quartz; P Read Montague Journal: Science Date: 2005-04-01 Impact factor: 47.728
Authors: Madelon M E Riem; Marinus H van IJzendoorn; Mattie Tops; Maarten A S Boksem; Serge A R B Rombouts; Marian J Bakermans-Kranenburg Journal: Neuropsychopharmacology Date: 2011-12-21 Impact factor: 7.853
Authors: Madelon M E Riem; Marian J Bakermans-Kranenburg; Suzanne Pieper; Mattie Tops; Maarten A S Boksem; Robert R J M Vermeiren; Marinus H van Ijzendoorn; Serge A R B Rombouts Journal: Biol Psychiatry Date: 2011-04-05 Impact factor: 13.382
Authors: Franklin R Schneier; Anissa Abi-Dargham; Diana Martinez; Mark Slifstein; Dah-Ren Hwang; Michael R Liebowitz; Marc Laruelle Journal: Depress Anxiety Date: 2009 Impact factor: 6.505
Authors: Adam J Guastella; Stewart L Einfeld; Kylie M Gray; Nicole J Rinehart; Bruce J Tonge; Timothy J Lambert; Ian B Hickie Journal: Biol Psychiatry Date: 2009-11-07 Impact factor: 13.382
Authors: Wuyi Wang; Simon Zhornitsky; Herta H Chao; Ifat Levy; Jutta Joormann; Chiang-Shan R Li Journal: Behav Brain Res Date: 2019-10-20 Impact factor: 3.332
Authors: Jessie L Frijling; Mirjam van Zuiden; Saskia B J Koch; Laura Nawijn; Dick J Veltman; Miranda Olff Journal: Soc Cogn Affect Neurosci Date: 2015-09-17 Impact factor: 3.436